Literature DB >> 3469463

Monoclonal antibodies and synthetic tumor-associated glycoconjugates in the study of the expression of Thomsen-Friedenreich-like and Tn-like antigens on human cancers.

B M Longenecker, D J Willans, G D MacLean, S Selvaraj, M R Suresh, A A Noujaim.   

Abstract

Synthetic carbohydrate haptens, which are conjugated to carrier human serum albumin molecules [synthetic tumor-associated glycoconjugates (S-TAGs)], were used to immunize mice for monoclonal antibody (MoAb) production. Two of the S-TAGs were composed of haptens related to the Thomsen-Friedenreich (TF) antigen, and their structures are beta Gal(1----3)-beta GalNAc (TF-beta) and beta Gal(1----3) alpha GalNAc (TF-alpha) (Gal = galactose; GaNAc = N-acetylgalactosamine). The third S-TAG was made up of Tn hapten groups of the structure alpha GalNAc-O-serine. MoAbs specific for TF-alpha and Tn were able to be generated. All MoAbs generated against TF-beta cross-reacted with TF-alpha but not with Tn. None of the TF-alpha-specific MoAbs reacted with human carcinomas, whereas several TF-beta and Tn MoAbs were found to react with most human lung, colon, and breast carcinomas. It is believed that this is the first report of the use of synthetic carbohydrate cancer antigens for the production of anticancer MoAbs.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3469463

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  18 in total

1.  Tumor immunolocalization using 124 I-iodine-labeled JAA-F11 antibody to Thomsen-Friedenreich alpha-linked antigen.

Authors:  Richa Chaturvedi; Jamie Heimburg; Jun Yan; Stephen Koury; Munawwar Sajjad; Hani H Abdel-Nabi; Kate Rittenhouse-Olson
Journal:  Appl Radiat Isot       Date:  2007-08-17       Impact factor: 1.513

Review 2.  Mucin glycoproteins in neoplasia.

Authors:  Y S Kim; J Gum; I Brockhausen
Journal:  Glycoconj J       Date:  1996-10       Impact factor: 2.916

3.  T cell recognition of a tumor-associated glycoprotein and its synthetic carbohydrate epitopes: stimulation of anticancer T cell immunity in vivo.

Authors:  C M Henningsson; S Selvaraj; G D MacLean; M R Suresh; A A Noujaim; B M Longenecker
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

Review 4.  MUC1 (CD227): a multi-tasked molecule.

Authors:  Vasso Apostolopoulos; Lily Stojanovska; Sharron E Gargosky
Journal:  Cell Mol Life Sci       Date:  2015-08-21       Impact factor: 9.261

5.  Identification of Tn antigen O-GalNAc-expressing glycoproteins in human carcinomas using novel anti-Tn recombinant antibodies.

Authors:  Yasuyuki Matsumoto; Matthew R Kudelka; Melinda S Hanes; Sylvain Lehoux; Sucharita Dutta; Mark B Jones; Kathryn A Stackhouse; Gabrielle E Cervoni; Jamie Heimburg-Molinaro; David F Smith; Tongzhong Ju; Elliot L Chaikof; Richard D Cummings
Journal:  Glycobiology       Date:  2020-04-20       Impact factor: 4.313

Review 6.  Molecular oncology in pancreatic cancer.

Authors:  S Gansauge; F Gansauge; H G Beger
Journal:  J Mol Med (Berl)       Date:  1996-06       Impact factor: 4.599

7.  Differential expression of the cancer associated antigens T (Thomsen-Friedenreich) and Tn to the skin in primary and metastatic carcinomas.

Authors:  J Kanitakis; I al-Rifai; M Faure; A Claudy
Journal:  J Clin Pathol       Date:  1998-08       Impact factor: 3.411

8.  The human repertoire of antibody specificities against Thomsen-Friedenreich and Tn-carcinoma-associated antigens as defined by human monoclonal antibodies.

Authors:  B Jansson; C A Borrebaeck
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

9.  Prognostic value of an assessment of ABH(0) isoantigens and Thomsen-Friedenreich (TF) antigen expression in patients with urinary bladder tumours.

Authors:  Z F Dobrowolski; D Duś; J Hałasa; C Radzikowski
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

10.  Application of chemically desialylated and degalactosylated human glycophorin for induction and characterization of anti-Tn monoclonal antibodies.

Authors:  M Duk; I Steuden; D Duś; C Radzikowski; E Lisowska
Journal:  Glycoconj J       Date:  1992-06       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.